TITLE

Milk Thistle for Alcoholic and/or Hepatitis B or C Liver Diseases–A Systematic Cochrane Hepato-Biliary Group Review with Meta-Analyses of Randomized Clinical Trials

AUTHOR(S)
Rambaldi, Andrea; Jacobs, Bradly P.; Iaquinto, Gaetano; Gluud, Christian
PUB. DATE
November 2005
SOURCE
American Journal of Gastroenterology;Nov2005, Vol. 100 Issue 11, p2583
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: Our objectives were to assess the beneficial and harmful effects of milk thistle (MT) or MT constituents versus placebo or no intervention in patients with alcoholic liver disease and/or hepatitis B and/or C liver diseases. METHODS: Randomized clinical trials studying patients with alcoholic and/or hepatitis B or C liver diseases were included (December 2003). The randomized clinical trials were evaluated by components of methodological quality. RESULTS: Thirteen randomized clinical trials assessed MT in 915 patients with alcoholic and/or hepatitis B or C liver diseases. The methodological quality was low: only 23% of the trials reported adequate allocation concealment and only 46% were considered double blind. MT versus placebo or no intervention for a median duration of 6 months had no significant effects on all-cause mortality (relative risk (RR) 0.78, 95% confidence interval (CI) 0.53–1.15), complications of liver disease, or liver histology. Liver-related mortality was significantly reduced by MT in all trials (RR 0.50, 95% CI 0.29–0.88), but not in high-quality trials (RR 0.57, 95% CI 0.28–1.19). MT was not associated with a significantly increased risk of adverse events. CONCLUSIONS: Based on high-quality trials, MT does not seem to significantly influence the course of patients with alcoholic and/or hepatitis B or C liver diseases. MT could potentially affect liver injury. Adequately conducted randomized clinical trials on MT versus placebo may be needed.
ACCESSION #
18613681

 

Related Articles

  • Seroprevalence of hepatitis B and C virus infections: Results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Rotermann, Michelle; Langlois, Kellie; Andonov, Anton; Trubnikov, Maxim // Health Reports;Nov2013, Vol. 24 Issue 11, p3 

    Background Chronic hepatitis B (HBV) and C (HCV) virus infections can lead to liver failure, liver cancer, and death. In Canada, prevalence studies of HBV and HCV have been limited to regional and special populations. Data and methods Data are from cycles 1 (2007 to 2009) and 2 (2009 to 2011) of...

  • Advances in the Treatment of Chronic Viral Hepatitis. Koff, Raymond S. // JAMA: Journal of the American Medical Association;8/11/99, Vol. 282 Issue 6, p511 

    Discusses chronic viral hepatitis. Its position as the predominant chronic liver disease in the United States; Viruses responsible for the disease; Statistics related to the disease; Methods of diagnosis and treatment; Comparison of hepatitis C and hepatitis B & D; Future prospects.

  • Rheumatic manifestations of hepatitis B and C and their association with viral load and fibrosis of the liver. Aydeniz, Ali; Namiduru, M.; Karaoglan, I.; Altindag, O.; Yagiz, E.; Gursoy, S. // Rheumatology International;Feb2010, Vol. 30 Issue 4, p515 

    The objective of this study is to investigate rheumatologic manifestations of hepatitis B and C and their relation with viral load and degree of hepatic fibrosis. Thirty-six HBV and 36 HBV patients were included. Liver biopsy was performed for all participants. We detected arthralgia...

  • Exacerbation of Chronic Active Hepatitis Type B after Short-Term Corticosteroid Therapy Resulting in Fatal Liver Failure. Laskus, Tomasz; Slusarczyk, Janusz; Cianciara, Janusz; Loch, Teresa // American Journal of Gastroenterology;Oct1990, Vol. 85 Issue 10, p1414 

    The case of a 36-yr-old male with chronic active type B hepatitis in whom 4-wk prednisone therapy resulted in prolonged and fatal exacerbation of liver disease is described. Thus, short-term corticosteroid therapy may in some patients have disastrous effects on the course of chronic active...

  • Relationship of Aminotransferases to Liver Histological Status in Chronic Hepatitis C1. Haber, Marian M.; West, A. Brian; Haber, Alan D.; Reuben, Adrian // American Journal of Gastroenterology;Aug1995, Vol. 90 Issue 8, p1250 

    Objectives: Serum aminotransferase levels characteristically fluctuate in chronic hepatitis C, but their relationship to grade (i.e., inflammatory activity) and stage (i.e., degree of fibrosis) of liver disease is uncertain. We therefore correlated aminotransferase levels and liver biopsy...

  • Long-Term Outcome of Acute Hepatitis B and C in an Outbreak of Hepatitis in 1969—72. Bläckberg, J.; Braconier, J. H.; Widell, A.; Kidd-Ljunggren, K. // European Journal of Clinical Microbiology & Infectious Diseases;Jan2000, Vol. 19 Issue 1, p21 

    The objective of this study was to investigate the epidemiology, etiology, and long-term outcome of an extended outbreak of acute hepatitis that occurred in an area of Sweden between 1969 and 1972. The outbreak was analyzed retrospectively by retesting stored frozen serum samples for the...

  • Chronic viral hepatitis in children: any role for the pathologist? Guido, Maria; Bortolotti, Flavia // Gut;Jul2008, Vol. 57 Issue 7, p873 

    The article discusses the role of pathologist in handling children with chronic viral hepatitis. It is outlined that chronic hepatitis has been established by human hepatitis viruses, hepatitis B (HBV) and hepatitis C (HCV). In the complex and dynamic scenario of chronic HBV and HCV infection,...

  • A brighter future in the fight against hepatitis.  // Nature Medicine;Jul2013, Vol. 19 Issue 7, p791 

    The article looks at efforts to prevent and treat viral hepatitis worldwide. The World Health Organization (WHO) has made July 28 the official World Hepatitis Day to increase public awareness of the disease. The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) and their role in...

  • Significance of HBV DNA in the Hepatic Parenchyma from Patients with Non-B, Non-C Hepatocellular Carcinoma. Nakai, Takuya; Shiraishi, Osamu; Kawabe, Takashi; Ota, Hideo; Nagano, Hiroaki; Shiozaki, Hitoshi // World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1338 

    Introduction: The etiologic and prognostic factors for non-B, non-C hepatocellular carcinoma (HCC), which is defined by its seronegativity for both hepatitis B surface antigen and hepatitis C virus (HCV) antibody, remain unclear. Methods: Nonneoplastic liver tissue from 46 patients with non-B,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics